Australian Biotechnology News

Stories about: Apollo

  • +

    Apollo's proteins sold to NZ 24/06/2008 11:29:34

    NZ biotech Symansis has bought Apollo Cytokine Research.
  • +

    Apollo signs $500,000 deal with Symansis 11/06/2008 11:36:34

    Includes the sale of assets and licensing of proprietary techniques
  • +

    This week in Oz biotech 20/03/2008 12:53:31

    Apollo aborts mission, investment fund licensed, biotechs move into Phase II trials and NuSep sorts its sperm.
  • +

    Apollo scores big with Millipore 21/08/2007 15:34:34

    Apollo Life Sciences signs agreement with Millipore for LIF protein.
  • +

    Transdermal delivery posts positive results 06/08/2007 11:16:32

    Apollo Life Sciences is testing its transdermal delivery technology in OTC applications before clinical trials for therapeutics.
  • +

    Apollo develops needle-free topical vaccine 30/04/2007 16:23:58

    Australian bitoech Apollo Life Sciences has released results of preliminary trials of a transdermally delivered tetanus vaccine.
  • +

    BIO profile: Apollo prepares for lift-off 11/04/2007 10:45:50

    Two major pre-clinical breakthroughs have set Apollo Life Sciences on the road to commercialising the company's large molecule delivery systems, with orally delivered insulin and TNF blockers just two of its targets.
  • +

    Australia at BIO 2007 03/04/2007 12:11:49

    The special BIO 2007 issue of Australian Life Scientist is out now.
  • +

    Oral delivery of TNF blockers 22/02/2007 11:10:24

    TNF blocker a second major application for Apollo Life Sciences' Oradel platform, currently in development for oral insulin.
  • +

    Apollo gets ready for lift-off 02/02/2007 10:47:27

    Successful toxicology trials means Apollo Life Science can move towards human clinical trials for its insulin in tablet form.
  • +

    Needle-free psoriasis treatment progresses 20/10/2006 10:47:33

    People suffering from severe psoriasis may soon find symptom relief without injections, after a cream-based treatment being developed by Sydney biotechnology company Apollo Life Sciences outperformed current market-leading drugs in pre-clinical studies.
Additional Resources
Newsletter Subscription
Sign up for our Australian Life Scientist newsletters!
 
Jobs